TABLE 1.
Baseline characteristics of the 115 patients with Crohn’s disease.
| Characteristics | n, frequency (%) or median (IQR) |
|---|---|
| Male | 80 (69.6) |
| Age (years) | 32.87 (16–68) |
| Crohn’s disease phenotype at indusion (Montreal classification) a | |
| L1 (ileal disease) | 22 (19.1) |
| L2 (colonic disease) | 18 (15.7) |
| L3 (ileocolonic disease) | 73 (63.5) |
| L4 (upper gastrointestinal disease) | 2 (1.7) |
| B1 (inflammatory predominant) | 91 (79.1) |
| B2 (stricturing disease) | 24 (20.9) |
| B3 (penetrating disease) | 0 |
| P b | 56 (48.7) |
| Previous intestinal resection | 26 (22.6) |
| Previous treatment with inflizimab | 31 (27.0) |
| Concomitant drugs at the time of inclusion 5-aminosalicylates | 3 (2.6) |
| Thiopurines | 7 (6.1) |
| Enteral nutrition c | 8 (7.0) |
| No concomitant drugs | 97 (84.3) |
| Clinical activity d | 102 (88.7) |
a
Satsangi et al.
b
Perianal disease modifier added to B when concomitant perianal disease is present.
c
Total enteral nutrition included.
d
Crohn’s disease activity index >150 and Crohn’s disease endoscopic index of severity >3.